The ICS results demonstrate the strongest anti-B16 tumor cell responses amongst CD8+ TILs recovered from animals receiving DC-MAA Peptide or DC–Pool (which include MAA) Peptide vaccines (Figure 1E), with all antigen-loaded DC-based vaccines eliciting statistically elevated T cell responses against B16 melanoma cells vs. untreated or Ag-unloaded DC vaccinated mice (p < 0.05). The gene discussed is CD8A; the disease is melanoma.